7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
1/19
-(50(0$/=$&
0$7(5,$0(',&$20(23$7,&$',,00812/2*,$&/,1,&$
1829$,36$(',725(
Hormones
Cytokines
neuropeptidesGrowtH faCtors
APPENDIX
HomeopatHic materia medicaof clinical immunology
The vision of
Physiological Regulating Medicine
on the use of physiological low doses of
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
2/19
All rights reserved.
Reproduction under any form are prohibited without written permission of pubblisher
2010 J mlzc cgh
2010 nv i e l, h
.v. - -l: @v.
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
3/19
1
Hormones
Cytokines
neuropeptides
GrowtH faCtors
APPENDIX
The vision of
Physiological Regulating Medicine
on the use of physiological low doses of
is based on a revolutionary ideain the medical field: restoring the initial physiological conditions of a sick body by usingthe same biological molecules that are usually present in the body and which control and
guide its functions in healthy conditions.
To be precise, these molecules are very well known and extensively studied in MolecularBiology, and it is no mere chance that they are called messenger molecules- substances that
can convey the right instructions for correct function to the various cells of the body.These molecules include
(Ner-vous System messen-gers),(Endocrine System mes-sengers),(Immune System mes-
sengers).There are also
,which are essential tissueregulating and stimulatingmolecules.
It has been acknowledged that these substances play a decisive role in determining eitherhealth or disease, and today it has been ascertained that every disease is the expression of
changes in concentrations either of an increase or of a reduction of these substances.All international medical research is focusing on the study of messenger molecules; thepositive (healing) or negative (disease) fate of several pathological conditions depends onthem and on the possibility of using them for therapeutic purposes
PSYCHE
SOMAPSYCHE
P.N.E.I. NETWORKP.N.E.I. NETWORK
AND MESSENGER MOLECULESAND MESSENGER MOLECULES
INTERLEUKINS
HORMONES
NEUROPEPTIDES
HORMONES
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
4/19
2
For instance, correcting Immune System alterations through the use of cytokines and en-docrine diseases with hormones is one of the most fascinating and innovative objectives ofresearch centered on applying Molecular Biology to Medicine. But the clinical applicationof this know-how has always come to a standstill when faced with the side effects caused
by the high doses of these substances that have been routinely used until today.
The pharmaceutical technique known as enablesthe administration of OF HORMONES, NEUROPEPTIDES,CYTOKINES AND GROWTH FACTORS to achieve the same therapeutic results ashigh doses but without any side effects.
In November 2009 the prestigious international scientific
reviewpublished the article Low dose oral administration
of cytokines for treatment of allergic asthma. The paperenlarged on the effects of low doses of SKA-activated cytokinesin the treatment of allergic asthma, proving in a clear, evidentand especially reproducible manner that the low dosesadministered during the study produced the same effects ashigh doses in changing a series of clinical and laboratory
parameters typical of the allergic condition.
The opens a new era in options for the clinical use of messenger moleculesand concretises the scientific dream of using biological molecules, such as cytokines,hormones and neuropeptides, in low doses (the only doses that can avoid side effects).
A new frontier has most likely been set for pharmaceutical industries and in the field ofMolecular Biology, and both Italian researchers and the Italian industry are paving the wayin this sector.
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
5/19
3
Low physiological doses of cytokines activated with the SKA procedure are marketed in ahydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, whichcorresponds to a homeopathic dilution of 4CH1.
The standard posology is 20 drops twice a day.Sublingual administration is recommended.
The duration of therapy differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massive dosetherapy can be applied with 10 drops every 20 minutes for maximum 2 hours.
Cytokines can be prescribed following two trends.
if the pathological condition is the expression of a ofa certain cytokine, the same cytokine will be used;
if the pathological condition is the expression of an of a certaincytokine, the so-called opposing cytokine will be used.
the cytokine is prescribed to suit the symptoms of the patient.
1 Single cytokines are also available in dilutions of 15CH and 30CH, which are at times
used as maintenance treatment to stabilize therapeutic results achieved with the use of di-lution 4CH.
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
6/19
4
Anti IL-1 alpha Anti IL-1 alpha 4 CH IL-1 4CH
Anti IL-1 beta Anti IL-1 beta 4 CH IL-1 4CH
GCSF GCSF 4CH IL-10 4CH / IL-4 4CH
IL-1 IL-1 4CH
Anti IL-1 alpha 4CH
Anti IL-1 beta / IL-10 4CHIL-2 IL-2 4CH IL-11 4CH
IL-3 IL-3 4CH IL-10 4CH
IL-4 IL-4 4CH INF-gamma 4CH / IL-12 4CH
IL-5 IL-5 4CH TGF-beta 4CH
IL-6 IL-6 4CH
Acute inflammation:
IL-4 4CH/INF- 4CHChronic inflammation:TNF Alpha 4CH
IL-7 IL-7 4CH IL-10 4CH / TGF-b 1 4CH
IL-8 IL-8 4CH IL-10 4CH / TGF-b 1 4CH
IL-9 IL-9 4CH IL-10 4CH
IL-10 IL-10 4CH IL-1 4CH / TNF 4CH
IL-6 4CHIL-11 IL-11 4CH IL-2 4CH
IL-12 IL-12 4CH IL-4 4CH/IL-10 4CH
INF alpha INF alpha 4CH IL-4 4CH
INF gamma INF gamma 4CH IL-4 4CH
TGF-beta 1 TGF-beta 4CH IL-12 4CH
TNF TNF-alpha 4CH Anti IL-1 4CH+IL-10 4CH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
7/19
5
Pain syndromes Acute inflammatory diseases Fever
Pain syndromes Acute inflammatory diseases Fever
Asthenia Sleep disorders Appetite disorders (excessive appetite)
Immunodeficiencies General sickness Subacute pain syndromes Localised inflammations Aging Complementary treatment for tumours Weariness, adynamia Burning sensation in the mouth Sensitivity to viral infections
Haemopoiesis disorders Side effects associated with chemotherapy, radio-
therapy and antiviral treatments Early aging Memory loss Digestive disorders Vertigo with vomiting Skin eruptions Erratic pains
Basic treatment for autoimmune diseases Chronic inflammatory diseases Spastic cramp-like pain Mental fatigue
Intestinal parasitosis Bruise-induced pain Constipation and flatulence Abdominal pains (cramp-like) RRI with IgA deficiency
General sickness Complementary therapy for tumours Appetite disorders (excessive appetite)
Recurrent infections Asthenia Growth and development disorders
Pulsating pain Nervous breakdown and tiredness
Activation of chemotaxis Productive cough Catarrh Acute and chronic stress
Asthenia and drowsiness Erythroid proliferation disorders (synergywith erythropoietin)
Neuralgic pain Chronic catarrh Water retention
Chronic inflammatory diseases Itching with a burning sensation Reddened mucous tissue Chronic pain syndromes Vomiting/loss of appetite
Pyrosis and gastric acid hypersecretion Memory disorders Haemopoiesis disorders Psoriasis Abdominal bloating Basic regulation of patients undergoing immunotherapy Growth and development disorders Pulsating pain Nervous breakdown and tiredness
Allergies Food intolerances Complementary therapy for tumours Recurrent nighttime cough Nasal obstruction and nose itch Paroxysmal sneezing Allergy-induced hyperlacrimation Swollen and reddened skin
Recurrent viral infections Articular pain Asthenia Sudden pain with numbing Painful muscle spasms
Chronic viral infections Allergic syndromes Complementary therapy for tumours Asthenia Spastic muscle pain
Complementary therapy for tumours
Chronic bacterial infections Confusion at night with sleep disorders Myalgia and stiffness especially in the morning
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
8/19
6
2 For single hormones or single neuropeptides marketed in dilutions of 4CH, dilutions of15CH/30CH are also available. They are at times used as maintenance therapy to stabilisetherapeutic results achieved with the use of the 4CH dilution.
3 Single hormones are also available in a 30DH dilution, which is at times used as maintenancetreatment to stabilise therapeutic results achieved with the use of dilution 6DH.
Low physiological doses of hormones activated with the SKA procedure are marketed in ahydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, whichcorresponds to the homeopathic dilution of 4CH for some (Beta-Endorphin, Melatonin,Somatostatin)2, and in nanograms/ml, corresponding to the homeopathic dilution of 6DHfor others3.
The standard posology is 20 drops twice a day.Sublingual administration is recommended.
The duration of treatment differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massive dosetherapy can be applied with 10 drops every 20 minutes for maximum 2 hours.
Hormones and neuropeptides can be prescribed following two trends.
if the pathological condition is the expression of a ofa certain hormone or neuropetide, the same hormone will be used;
If the pathological condition is the expression of an of a certain
hormone, the so-called opposing hormone will be used consistently with the physiologyof negative feedback.
the hormone is prescribed to suit the symptoms of the patient.
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
9/19
7
ACTH ACTH 6DH TSH 6DH
Beta-ENDORPHIN Beta-ENDORPHIN 4CH no opposing hormone
Beta-ESTRADIOL beta-ESTRADIOL 6DH PROGESTERON 6DH
CALCITONIN CALCITONIN 6DH PARATHYROIDHORMONE 6DH
DOPAMIN DOPAMIN 6DH
SEROTONIN 6DH
MELATONIN 4CH
PROLACTIN 6DH
FSH FSH 6DH beta-ESTRADIOL 6DH
GH IGF-1 6DH SOMATOSTATIN 4CH
LH LH 6DH PROGESTERON 6DH
MELATONIN MELATONIN 4CH PROLACTIN 6DH
OXYTOCIN OXYTOCIN 6DHPROGESTERONE 6DH
Beta-ESTRADIOL 6DH
PARATHYROID
HORMONE
PARATHYROID
HORMONE 6DHCALCITONIN 6DH
PROGESTERONE PROGESTERONE 6DH Beta-ESTRADIOL 6DH
PROLACTIN PROLACTIN 6DH MELATONIN 4CH
SOMATOSTATIN SOMATOSTATIN 4CHIGF-1 6DH
PROLACTIN 6DH
T3 T3 6DH SOMATOSTATIN 4CH
T4 T4 6DH SOMATOSTATIN 4CH
TSH TSH 6DH ACTH 6DHSOMATOSTATIN 4CH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
10/19
8
Asthenia Aging Chronic stress Loss of appetite Hypervagotonia
Pain of diverse origins
Female hormone cycle disorders and infertility Aging Hot flushes Sagging skin Stress
Osteoporosis Bone pain
Chronic Fatigue Syndrome Mental Strain Mood disorders Lack of attentiveness Lack of sexual desire Decreased sexual arousal Supportive therapy of Parkinson's disease
Female hormone cycle disorders and infertility Aging Ovarian polycystosis Low female libido
Aging Female hormone cycle disorders and infertility Low male libido
Sleep disorders Circadian rhythm and organ function alterations Stress Mood disorders with unstable mood Complementary therapy for tumours Hypersympathicotonia
Jet lag
Mood disorders Social phobya Decreased sexual satisfaction Supportive treatment during delivery Supportive treatment of Autism
Cramp-like pains Asthenia
Premenstrual syndrome Female hormone cycle disorders and infertility Menstrual pain Intermenstrual spotting Ovarian polycystosis
Mood disorders with unstable mood Muscle weakness
Mood disorders with unstable mood Headache Diet disorders
Oncological diseases Hyperthyroidism
Hypothyroidism Tendency toward overweight
Growth disorders Physical asthenia Neurasthenia
Sleep disorders Mood disorders and unstable mood
Neurasthenia Water retention
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
11/19
Low physiological doses of growth factors activated with the SKA procedure are marketedin a hydroalcoholic solution of 30 ml bottles. The drug concentration is in picograms/ml,which corresponds to a homeopathic dilution of 4CH4.
The standard posology is 20 drops twice a day.Sublingual administration is recommended.
The duration of therapy differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massivedose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.
Growth factors can be prescribed following two trends.
if the pathological condition is the expression of a ofa certain growth factor, the same growth factor will be used.
the growth factor is prescribed to suit the symptoms of the patient.
4 Single growth factors are also available in dilutions 15C and 30C, which are at times used
as maintenance therapy to stabilise therapeutic results achieved with the use of dilution4CH.
9
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
12/19
10
Neurological damage (duringdevelopment or subsequent to injuries)
Outcome of psychic shock Mental tiredness Stress Autism Cerebral aging Tingling and numbing of hands
and feet
Muscle stiffness
Neurological damage (duringdevelopment or subsequent to injuries) Sight disorders Cerebral aging Appetite control Cerebral aging
Skin rashes Skin aging Itching Chapped skin Gastric acid hypersecretion Feeling of heaviness in the epigastrium
with soreness Blurred vision with scintillating scotomas Hypersensitivity to pain
Aging Cicatrisation difficulty Articular symptoms with limited movement
Skin aging
Mental tiredness Muscle weakness Damaged myelin sheath
Sensitivity to infectious diseases Immune response triggered in chronic
and autoimmune diseases.
Growth disorders Aging Memory disorders (stimulates
hippocampus function)
Neuralgic pain Memory disorders Mood disorders
Skin thinning and ulcers Loss of strength in limbs, easy tiredness Sadness and loss of interest
Muscle weakness Mood disorders CNS and PNS diseasesNeurological damage (during
development and subsequent to injuries)
Muscle weakness Mood disorders CNS and PNS disorders Neurological damage (during
development and subsequent to injuries) Pain syndromes
Aging Wrinkles Mytogenic activity
Chronic pain syndromes Autoimmune diseases Chronic inflammations
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
13/19
11
INTERLEUKIN-5 4CH
INTERLEUKIN-11 4CH
INTERLEUKIN-8 4CH
Anti INTERLEUKIN-1alpha 4CH/Anti INTERLEUKIN-1beta 4CH
INTERLEUKIN-2 4CH / FGF 4CH / IGF-1 4CH / PDGF 4CH /ACTH 6DH / Beta-ESTRADIOL 6DH / FSH 6DH / LH 6DH
INF-gamma 4CH+INTERLEUKIN-12 4CH
INTERLEUKIN-12 4CH + INTERFERON-gamma 4CH /INTERLEUKIN-13 4CH
INTERLEUKIN-12 4CH
CNTF 4CHINTERLEUKIN-1 beta 4CH /
INTERLEUKIN-6 4CH
INF-alpha 4CH
FGF 4CH
INTERLEUKIN-1 beta 4CH / INTERLEUKIN-7 4CH /INF-alpha 4CH / INF-gamma 4CH / ACTH 6DH /
PARATHYROID HORMONE 6DHINTERLEUKIN-9 4CH
BDNF 4CH
TGF-beta 1 4CH
INTERLEUKIN-11 4CH
INTERLEUKIN-4 4CH
EGF 4CH
CALCITONIN 6DHINTERLEUKIN-5 4CH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
14/19
12
INTERLEUKIN-2 4CH
INTERLEUKIN-8 4CH
BDNF 4CH / CNTF 4CH
EGF 4CH
INTERLEUKIN-8 4CH
TNF-alpha 4CH
INTERLEUKIN-9 4CH
DOPAMIN 6DH
TGF-beta 1 4CH
INTERLEUKIN-4 4CH /
INTERLEUKIN-10 4CHInterleuchina-10 4CH / Beta-ENDORFINA 4CH /TGF-beta 1 4CH
INF-gamma 4CH
ACTH 6DH
FGF 4CH
MELATONIN 4CH
NT3 4CH/NT4 4CH
SOMATOSTATIN 4CH /INTERLEUKIN-12 4CH / INTERFERON-gamma 4CH /INTERLEUKIN-2 4CH / MELATONIN 4CH / TNF-alpha 4CH
TNF-alpha 4CH
INTERLEUKIN-5 4CH
PARATHYROID HORMONE 6DH
INTERLEUKIN-10 4CH + Anti IL-1
G1 4CH
DOPAMIN 6DH
OXYTOCIN 6DH
SEROTONIN 6DH
INTERLEUKIN-3 4CH
DOPAMIN 6DH
INTERLEUKIN-3 4CHINTERLEUKIN-3 4CH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
15/19
13
INTERLEUKIN-9 4CH
EGF 4CH
Beta-ESTRADIOL 6DH /
FSH 6DH / LH 6DH / PROGESTERON 6DHAnti IL-1 4CH
INTERLEUKIN-12 4CH
EGF 4CH
INTERLEUKIN-2 4CH / INTERLEUKIN-6 4CH
INTERLEUKIN-7 4CH /INTERLEUKIN-11 4CH
IGF-1 4CH / T4 6DHSEROTONIN 6DH
INTERLEUKIN-3 4CH / INTERLEUKIN-11 4CH
EGF 4CH
ACTH 6DH
MELATONIN 4CH
SOMATOSTATIN 4CH
T3 6DHBeta-ESTRADIOL 6DH
GCSF 4CH
INTERLEUKIN-2 4CH
PROGESTERON 6DH
INTERLEUKIN-5 4CH
EGF 4CH
INTERLEUKIN-10 4CH
MELATONIN 4CH
DOPAMIN 6DH
DOPAMIN 6DH
INTERLEUKIN-2 4CH
ACTH 6DH
NGF 4CHFSH 6DH / OXYTOCIN6DH / DOPAMIN 6DH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
16/19
14
LH 6DH / DOPAMIN 6DH
NGF 4CH / IGF-1 4CH (stimulates hippocampusfunction) / INTERLEUKIN-11 4CH
INTERLEUKIN-3 4CH
PROGESTERON 6DH
INTERLEUKIN-4 4CH
DOPAMIN 6DH
BDNF 4CH / G1 4CH
NGF 4CH / NT3 4CH / NT4 4CH /OXYTOCIN 6DH / DOPAMIN 6DH
MELATONIN 4CH /SEROTONIN 6DH / TRYPTOPHAN 6DH
G1 4CH / NT3 4CH / NT4 4CH / PROLACTIN 6DH
TNF-alpha 4CH
PDGF 4CH
INTERLEUKIN-12 4CH
INTERLEUKIN-7 4CH /INTERLEUKIN-11 4CH
NGF 4CH / INTERLEUKIN-9 4CHT4 6DH / TSH 6DH
BDNF 4CH / CNTF 4CH / NT3 4CH / NT4 4CH
CALCITONIN 6DH
BDNF 4CH
FSH 6DH / PROGESTERON 6DH
Beta-ENDORPHIN 4CHBeta-ENDORPHIN 4CH / Anti INTERLEUKIN-1 4CH /
NT4 4CH
INF-alpha 4CH
INTERLEUKIN-12 4CH
T4 6DH
INTERLEUKIN-7 4CH / INTERLEUKIN-11 4CH
PROGESTERON 6DH / Beta-ENDORPHIN 4CHINTERLEUKIN-8 4CH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
17/19
15
INTERLEUKIN-11 4CH / INTERLEUKIN-4 4CH /INTERLEUKIN-10 4CH
INTERLEUKIN-11 4CH
INTERLEUKIN-7 4CH
INTERLEUKIN-12 4CH
INF-alpha 4CH
INTERLEUKIN-10 4CH
INTERLEUKIN-5 4CH
NGF 4CH
Beta-ESTRADIOL 6DH
GCSF 4CH
INTERLEUKIN-2 4CH
INTERLEUKIN-3 4CH
CNTF 4CH
EGF 4CH / FGF 4CH
INTERLEUKIN-3 4CH
EGF 4CH
NGF 4CH
MELATONIN 4CH / TRIPTOPHAN 6DH /INTERLEUKIN-1 beta 4CH
OXYTOCIN 6DH
INTERLEUKIN-4 4CH
INF-gamma 4CH
BDNF 4CH
BDNF 4CH / Beta-ESTRADIOL 6DH / MELATONIN 4CH
INTERLEUKIN-2 4CH / Beta-ENDORPHIN 4CH
INF-alpha 4CH
OXYTOCIN 6DH
OXYTOCIN 6DH
DOPAMIN 6DH
INTERLEUKIN-12 4CHT3 6DH
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
18/19
BDNF 4CH
INTERLEUKIN-3 4CH
INTERLEUKIN-10 4CH
INTERLEUKIN-9 4CH / TSH 6DH
INTERLEUKIN-2 4CH
PDGF 4CH
16
7/31/2019 Citocinas Hormonas y Factores de Crecimiento.
19/19
-(50(0$/=$&
0$7(5,$0(',&$20(23$7,&$',,00812/2*,$&/,1,&$
1829$,36$(',725(
Hormones
Cytokines
neuropeptides
GrowtH faCtors
APPENDIX
HomeopatHic materia medica
of clinical immunology
The vision of
Physiological Regulating Medicine
on the use of physiological low doses of
Top Related